Recorded on: Sept. 24, 2019

Description: Regulatory expert John Balzano shares best practices for navigating legal and regulatory issues related to healthcare products and services in China. He discusses:

• Important new regulatory reforms in China related to drug development, including 60-day notification of clinical trial applications, priority review and GCP enforcement;
• Revisions to Human Genetic Resources (HGR) regulations;
• How to prepare for overseas inspections and compliance with emerging distribution and manufacturing rules; and
• How to make sense of the recent guidance documents coming out of China including guidance on foreign data and new application modules.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: John Balzano, Esq., Partner, Covington & Burling LLP

Recorded on: Sept. 19, 2019

Description: Quality systems expert Dan O’Leary shares insights on the EU-MDR’s extensive requirements for documenting, conducting and reporting clinical investigations, including which devices are exempt. He discusses:

• The role of the clinical investigation in the EU-MDR;
• Which device types require clinical investigations;
• How to integrate the EU-MDR and ISO/DIS 14155:2018; and
• The role of the Notified Body and Competent Authority.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Dan O’Leary, President, Ombu Enterprises, LLC

Recorded on: Sept. 17, 2019

Description: Regulatory expert Barbara Blumenfeld shares information on the FDA’s recently enforced interpretation of its stem cell regulatory framework. She discusses:

• The FDA regulatory framework in 21 CFR Part 1271 for human cells, tissues and cellular and tissue-based products (HCT/Ps);
• Enforcement efforts that the FDA has taken since November 2017, including the issuance of warning letters and industry letters and relevant court actions;
• The FTC’s October 2018 settlement with Regenerative Medical Group and Telehealth Medical Group (California) for false and misleading consumer advertising; and
• Various opportunities for the legal development and use of stem cells.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Barbara A. Binzak Blumenfeld, Ph.D., Shareholder, Buchanan Ingersoll & Rooney, PC

Recorded on: Aug. 27, 2019

Description: Device expert Connie Hoy shares best practices for implementation of the new Medical Device Single Audit Program (MDSAP) audit protocol. She discusses:

• The use of the Companion Document to prepare successfully for the MDSAP audit;
• The use of the quality system to ensure that an organization completely covers specific country requirements;
• The specifics of the registration review process; and
• How the MDSAP audit is conducted and how it differs from FDA inspections and ISO audits.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Connie Hoy, Senior Vice President, Regulatory Affairs, Cynosure

Recorded on: Aug. 22, 2019

Description: Industry expert Dan O’Leary shares best practices for preparing for the FDA’s 510(k) design change guidance documents. He discusses:

• The role of risk management (ISO 14971:2007) in the evaluation process;
• The decision-making process embodied in the flowcharts;
• The critera behind the flowchart decision boxes; and
• How to keep quality records that support your decision.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Dan O’Leary, President, Ombu Enterprises, LLC

Recorded on: Aug. 20, 2019

Description: Device expert James Pink shares best practices for preparing for the EU MDR deadline (May 26, 2020). He discusses:

• The new MDR classification system and how to apply it;
• New separate software rules and what they say;
• Stricter requirements for implantable devices; and
• The consequences of delay

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: James Pink, Executive Vice President, Consulting Services, National Sanitation Foundation

Recorded on: Aug. 15, 2019

Description: Research expert Mary Jo Lamberti and analytics expert Francis Kendall share best practices for the use of RWE and RWD to generate evidence and identify gaps and challenges. Tufts CSDD investigated 30 biopharmaceutical companies' use of RWD to generate evidence and showed the top measures for using RWE for return on investment, among other findings. They discuss:

• The types of technology used to access or collect RWD and evidence and partnerships that support usage;
• The significant challenges to using RWD as well as strategies and practices that impact return on investment or performance;
• The key drivers for change and the adoption of RWE; and
• The potential of RWE and how it may be used across the clinical development pipeline and a view on what will happen next in the domain.

Presentation: Download the presentation

Transcript: Download the transcript

Speakers: Mary Jo Lamberti, Associate Director of Sponsored Research and Research Assistant Professor, Tufts CSDD; Francis Kendall, Senior Director, Cytel

Recorded on: Aug. 8, 2019

Description: FDA staff member Sugato De and regulatory expert Peter Steiger share explain innovative strategies that companies can implement to support smarter, faster approvals. They discuss:

• Which wearables and sensors needs FDA approval;
• How to comply with the FDA’s final guidance on assessing wellness products and how that assessment is determined;
• Why blood pressure monitoring through wearables and sensors represents a new frontier in FDA regulation and should be watched closely by manufacturers; and
• Why the ingestibles category is one of the big new developments in the future of wearables.

Presentation: Download the presentation

Transcript: Download the transcript

Speakers: Sugato De, Vice President, Technical, PAREXEL; Peter Steiger, Vice President and Chief Scientific Officer, PAREXEL

Recorded on: Aug. 6, 2019

Description: FDA regulatory and life sciences expert Bethany Hills-Grois shares best practices for understanding the current policies and proposed changes to the drug pricing and reimbursement landscape. She discusses:

• How drug pricing policies may impact labeling and promotional activity;
• Practical tips on product data development to align with drug pricing policies;
• The drug pricing and reimbursement framework, including the roles the FDA, CMS and private parties plan; and
• Drug pricing proposals being considered in Congress and those expected to pass before the November elections.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Bethany Hills-Grois, Partner, Morris & Foerster

Recorded on: Aug. 5, 2019

Description: Quality Assurance expert Susan Schniepp shares best practices on regulatory expectations for the prevention of data integrity issues, problem areas for data integrity and strategies for detecting potential data integrity issues in operations. She discusses:

• Recent FDA warning letters citing data integrity;
• Data integrity code of conduct;
• Problem areas where data integrity issues can arise; and
• Strategies for detecting data integrity issues in QC and laboratory, computer systems and manufacturing.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Susan J. Schniepp, Distinguished Fellow, Regulatory Compliances Associates, Inc.